Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 6.66TCr 992.74Cr 885.63Cr 825.09Cr 750.86Cr 1.41TCr 96TCr 1.42TCr 9.97TCr 3.88TCr 49TCr 3.73TCr 3.65TCr 1,56900Cr P/E 2026 *
50.2x
P/E 2027 * 37.9x
Enterprise Value 6.19TCr 923.04Cr 823.44Cr 767.16Cr 698.14Cr 1.31TCr 89TCr 1.32TCr 9.27TCr 3.61TCr 45TCr 3.47TCr 3.39TCr 1,45800Cr EV / Sales 2026 *
7.65x
EV / Sales 2027 * 6.42x
Free-Float
62.13%
Yield 2026 *
0.72%
Yield 2027 * 0.96%
Manager TitleAgeSince
Chief Executive Officer 70 07/10/1998
Chief Executive Officer 49 19/01/2022
President - -
Director TitleAgeSince
Director/Board Member 49 18/07/2011
Chairman 70 07/10/1998
Director/Board Member 65 18/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 992.5Cr
+0.02%-3.52%+36.11%+111.11% 1,01900Cr
-1.21%-6.99%+34.08%+60.96% 62TCr
+1.12%-0.20%+13.62%+80.24% 46TCr
-3.30%-6.15%+56.45%+34.69% 36TCr
+0.93%-3.16%+21.65%+43.02% 33TCr
+0.12%-2.77%+10.70%+32.97% 27TCr
-0.89%-6.28%-7.00%+8.01% 24TCr
-0.01%-3.62%+35.28%+52.02% 22TCr
-0.08%-4.98%+28.34%+93.61% 18TCr
Average +0.19%-3.54%+25.47%+57.40% 41.08TCr
Weighted average by Cap. +0.44%-3.54%+28.50%+68.60%

Financials

2026 *2027 *
Net sales 808.44Cr 120.58Cr 107.57Cr 100.22Cr 91Cr 171.75Cr 12TCr 173.02Cr 1.21TCr 471.13Cr 5.93TCr 452.65Cr 442.89Cr 19TCr 967.73Cr 144.34Cr 128.76Cr 119.96Cr 109.17Cr 205.59Cr 14TCr 207.11Cr 1.45TCr 563.96Cr 7.09TCr 541.85Cr 530.15Cr 23TCr
Net income 135.15Cr 20Cr 18Cr 17Cr 15Cr 29Cr 1.94TCr 29Cr 202.44Cr 79Cr 990.86Cr 76Cr 74Cr 3.18TCr 179.49Cr 27Cr 24Cr 22Cr 20Cr 38Cr 2.58TCr 38Cr 268.86Cr 104.6Cr 1.32TCr 100.5Cr 98Cr 4.23TCr
Net Debt -467.34Cr -70Cr -62Cr -58Cr -53Cr -99Cr -6.71TCr -100.02Cr -700.01Cr -272.35Cr -3.43TCr -261.67Cr -256.03Cr -11TCr -365.59Cr -55Cr -49Cr -45Cr -41Cr -78Cr -5.25TCr -78Cr -547.6Cr -213.05Cr -2.68TCr -204.7Cr -200.28Cr -8.62TCr
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-